# US 2016/0355815 A1 · miR-29 Mimics and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355815 A1
- Document ID: US20160355815A1
- Status: Published application
- Kind: A1
- Application number: 15/175,636
- Filed: 2016-06-07
- Published: 2016-12-08
- Earliest claimed: 2014-09-08
- Assignees: Miragen Therapeutics, Inc.
- Applicants: miRagen Therapeutics, Inc.
- Inventors: Rusty L. MONTGOMERY; Christina M. DALBY; Eva VAN ROOIJ; Corrie GALLANT-BEHM
- Web page: https://patentgrep.com/patent/US20160355815A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2310/315: Phosphorothioates
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/343: having patterns, e.g. ==--==--==--
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2320/51: modulating the chemical stability, e.g. nuclease-resistance
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.

## Claims

### Claim 1

A miR-29 mimetic compound comprising:
a first strand of about 23 to about 26 ribonucleotides comprising a mature miR-29a, miR-29b, or miR-29c sequence; and
a second strand of about 22 to about 23 ribonucleotides comprising a sequence that is substantially complementary to the first strand and having at least one modified nucleotide, wherein the first strand has a 3′ nucleotide overhang relative to the second strand.

### Claim 2 (depends on 1)

The miR-29 mimetic compound of claim 1, wherein the first strand has one or more 2′ fluoro nucleotides.

### Claim 3 (depends on 1)

The miR-29 mimetic compound of claim 1, wherein the at least one modified nucleotide in the second strand is a 2′-O-methyl modified nucleotide.

### Claim 4 (depends on 1)

The miR-29 mimetic compound of claim 1, wherein the second strand has 1, 2, or 3 mismatches relative to the first strand.

### Claim 5 (depends on 4)

The miR-29 mimetic compound of claim 4, wherein the second strand contains mismatches from the 3′ end at positions 4, 13, and/or 16 relative to the first strand.

### Claim 6 (depends on 1)

The miR-29 mimetic compound of claim 1, wherein the second strand is linked to a cholesterol molecule at its 3′ or 5′ terminus.

### Claim 7 (depends on 6)

The miR-29 mimetic compound of claim 6, wherein the cholesterol molecule is linked to the second strand through at least a six carbon linker.

### Claim 8 (depends on 1)

The miR-29 mimetic compound of claim 1, wherein the nucleotides comprising the 3′ overhang in the first strand are linked by phosphorothioate linkages.

### Claim 9 (depends on 1)

The miR-29 mimetic compound of claim 1, wherein the first strand comprises a mature miR-29b sequence.

### Claim 10 (depends on 9)

The miR-29 mimetic compound of claim 9, wherein the first strand comprises a sequence selected from SEQ ID NO: 2, 18-21, or 31-34 and the second strand comprises a sequence selected from 1, 8-17, or 28-30.

### Claim 11 (depends on 9)

The miR-29 mimetic compound of claim 9, wherein the first strand comprises the sequence of SEQ ID NO: 19 and the second strand comprises the sequence of SEQ ID NO: 1.

### Claim 12 (depends on 9)

The miR-29 mimetic compound of claim 9, wherein the first strand comprises the sequence of SEQ ID NO: 19 and the second strand comprises the sequence of SEQ ID NO: 15.

### Claim 13 (depends on 1)

The miR-29 mimetic compound of claim 1, wherein the first strand comprises a mature miR-29a sequence.

### Claim 14 (depends on 13)

The miR-29 mimetic compound of claim 13, wherein the first strand comprises a sequence of SEQ ID NO: 6, 7 or 27 and the second strand comprises a sequence selected from SEQ ID NO: 3-5.

### Claim 15 (depends on 13)

The miR-29 mimetic compound of claim 13, wherein the first strand comprises the sequence of SEQ ID NO: 27 and the second strand comprises the sequence of SEQ ID NO: 5.

### Claim 16 (depends on 1)

The miR-29 mimetic compound of claim 1, wherein the first strand comprises a mature miR-29c sequence.

### Claim 17 (depends on 16)

The miR-29 mimetic compound of claim 16, wherein the first strand comprises a sequence of SEQ ID NO: 25, 26, or 35 and the second strand comprises a sequence selected from SEQ ID NO: 22-24.

### Claim 18 (depends on 16)

The miR-29 mimetic compound of claim 16, wherein the first strand comprises the sequence of SEQ ID NO: 35 and the second strand comprises the sequence of SEQ ID NO: 24.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising an effective amount of the miR-29 mimetic compound of claim 1, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier or diluent.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein the composition is an inhalation composition.

### Claim 21 (depends on 1)

A method of regulating an extracellular matrix gene in a cell comprising contacting the cell with the miR-29 mimetic compound of claim 1.

### Claim 22 (depends on 21)

The method of claim 21, wherein the cell is a mammalian cell.

### Claim 23 (depends on 22)

The method of claim 22, wherein the cell is a fibroblast or epithelial cell.

### Claim 24 (depends on 21)

The method of claim 21, wherein the cell is in vivo or ex vivo.

### Claim 25 (depends on 1)

A method of treating or preventing tissue fibrosis in a subject in need thereof comprising administering to the subject the miR-29 mimetic compound of claim 1.

### Claim 26 (depends on 25)

The method of claim 25, wherein the tissue fibrosis is cardiac fibrosis, pulmonary fibrosis, renal fibrosis, hepatic fibrosis, scleroderma, ocular fibrosis, cutaneous fibrosis.

### Claim 27 (depends on 26)

The method of claim 26, wherein the cutaneous fibrosis is selected from the group consisting of hypertrophic scarring, keloids, fibrosis of hands, joints or tendons and Peyronie's disease.

### Claim 28 (depends on 25)

The method of claim 25, wherein the administration is via inhalation.

### Claim 29 (depends on 25)

The method of claim 25, wherein the miR-29 mimetic compound or the pharmaceutical composition is administered via a metered dose inhaler, dry powder inhaler, nebulizer, heat vaporizer, soft mist inhaler, thermal aerosol inhaler, or an electrohydrodynamic-based solution misting inhaler.
